Efficacy and Safety of Roselle in Patients With Grade 1 Essential Hypertension: A Phase III, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial.
In: Clinical Trials Week, 2023-12-04, S. 208-208
serialPeriodical
Zugriff:
This document provides information about a Phase III clinical trial, NCT06141200, which is evaluating the efficacy and safety of NW Roselle, a powdered medicinal product developed by Natural Wellness, in the treatment of Grade 1 essential hypertension. NW Roselle combines extracts from Hibiscus Sabdariffa flowers and Olea europaea leaves. The trial will involve eligible participants who will be randomized to receive either NW Roselle or an active control, Captopril. Throughout the trial, participants will undergo assessments, vital sign monitoring, and laboratory tests to monitor their health and response to treatment. Adherence to treatment and any potential adverse events will also be tracked. The estimated enrollment for the trial is 286 participants, and the estimated completion date is April 2025. The document also includes contact information for the primary and backup contacts for the trial. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Efficacy and Safety of Roselle in Patients With Grade 1 Essential Hypertension: A Phase III, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial.
|
---|---|
Zeitschrift: | Clinical Trials Week, 2023-12-04, S. 208-208 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|